First-in-Human Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of Single Doses of NTM-1633, a Novel Mixture of Monoclonal Antibodies against Botulinum Toxin E
Shruti M. Raja, Jeffrey T. Guptill, Vern C. Juel, Emmanuel B. Walter, Michael Cohen‐Wolkowiez, Heather Hill, Eli A. Sendra, B. Hauser, Piper Jackson, Milan T. Tomic, Yarida A. Urbina Espinoza, Geeta K. Swamy
Abstract
). NTM-1633 also demonstrated low immunogenicity. NTM-1633 is well tolerated at the administered doses. The favorable safety, PK, and immunogenicity profile supports further development as a treatment for BoNT/E intoxication and postexposure prophylaxis.
Topics & Concepts
TolerabilityImmunogenicityMedicinePharmacokineticsPlaceboAdverse effectPharmacologyCmaxInternal medicinePharmacodynamicsImmunologyAntibodyPathologyAlternative medicineBotulinum Toxin and Related Neurological DisordersHereditary Neurological DisordersNeurological disorders and treatments